Accelerate your CDMO or DTC pipeline. Map the exact physiochemical constraints, bioavailability synergies, and optimal delivery mechanisms for Eclipta alba (Wedelolactone).
Wedelolactone functions as a potent inhibitor of NF-κB signaling and 5-lipoxygenase, exerting significant hepatoprotective and anti-inflammatory effects through the modulation of pro-inflammatory cytokine expression and oxidative stress pathways.
5281813
314.25 g/mol
2.4
1,8,9-trihydroxy-3-methoxy-[1]benzofuro[3,2-c]chromen-6-one
Every active compound behaves uniquely based on the physical matrix it is suspended in. Below are the known physical chemistry challenges for Eclipta alba (Wedelolactone) across standard consumer modalities.
The hygroscopic nature of Eclipta alba extract requires moisture-resistant HPMC capsules to prevent clumping and degradation of the coumestan content.
The inherent bitterness and dark pigment of the extract necessitate high-intensity masking agents and may result in undesirable darkening of the pectin matrix.
The high therapeutic dose required for systemic efficacy exceeds the typical 50mg payload capacity of thin-film polymer matrices.
Ready to launch a product featuring Eclipta alba (Wedelolactone)? Skip months of expensive wet-lab iterations. Generate a manufacturer-ready formulation in hours, instantly screened for physical incompatibilities and global regulatory compliance.
Build Science-Backed FormulationNeed absolute proof that your Eclipta alba (Wedelolactone) extract actually absorbs? Stop blindly combining generic powders. Run a physics-based PBPK simulation to mathematically engineer peak clinical efficacy and targeted plasma concentrations.
Simulate BioavailabilityIs your Eclipta alba (Wedelolactone) payload degrading in the capsule before the expiration date? Stop waiting for costly bench testing. Run an accelerated digital twin to precisely model oxidation pathways and pH shifts before finalizing a manufacturing run.
Model Active Degradation